Bachem Holding (BANB · SIX)
The Nvidia of Peptides
Bachem manufactures the complex chemical ingredients used by global drug companies to produce blockbusters like Ozempic and other weight-loss treatments.
Bull case for Bachem Holding
A Brand-New Factory, Already Sold Out
World's most advanced peptide plant just opened, largely pre-booked, driving 35–45% guided local-currency growth.
Regulation Is Steering Demand Its Way
FDA move against unlicensed compounders and US onshoring rules both favour licensed Western manufacturers.
From Building Costs to Cash Generation
Barely any debt, plus CHF 369m in customer prepayments, funds the final stretch of expansion.
Bear case for Bachem Holding
A Handful of Customers Matter a Lot
Revenue leans on a handful of huge customers, visible in sharp country-by-country swings.
The New Factory Still Has to Prove Itself
Chairman himself flags that "things can go wrong" scaling complex production processes.
Riding on One Drug Class, and a Strong Franc
Chairman's own top risk is GLP-1 setbacks, with a strong franc adding pressure.